42
T. Tadmor
Potential conflict of interest: A disclosure form provided by the author is available with the full text of this article at
www.informahealthcare.com/lal.
References
1. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
2. Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116: 595–597.
3. Dasanu CA, Ichim T, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf 2010;9:55–64.
4. Arons E, Sorbara L, Raffeld M, et al. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 2006;55:1100–1110.
5. Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is con- sistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009;145:665–667.
6. Ruco L, Procopio A, Maccallini V, et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983;61:1132–1137.
7. Urba W, Baseler M, Kopp W, et al. Deoxycoformycin- induced immunosuppression in patients with hairy cell leukemia. Blood 1989;73:38–46.
8. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8:848–855.
9. Seymour JF, Talpaz M, Kurzrock R. Response duration and
recovery of CD4þ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow- up. Leukemia 1997;11:42–47.
10. Seymour JF, Kurzrock R, Freireich E, Estey E. 2-Chloro- deoxyadenosine induces durable remissions and prolonged
suppression of CD4þ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906–2911.
11. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83: 3672–3681.
12. Schirmer M, Hilbe W, Geisen F, Thaler J, Konwalinka G. T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Acta Haematol 1997;97:180–183.
13. Federico M, Zinzano PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow- up. J Clin Oncol 2002;20:638–646.
14. Hisada M, Chen B, Jaffe E, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007;99:215–222.
15. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow- up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981–2986.
16. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92: 1160–1164.
17. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–3015.
18. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
19. Leupin N, Schuller JC, Solenthaler M, et al. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospec- tive multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma 2010;51:613–619.
20. Todd SA, Morris TC, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma 2002;43:1343–1344.
21. Hassan R, Gupta M, Kern W, Ozer H. Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature. Leuk Lymphoma 2004;45:2149–2152.
22. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:2056–2062.
23. Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2- chlorodeoxyadenosine therapy. Eur J Haematol 2001;66:7–10.
24. Siegel RS, Hakimian D, Spies W, et al. Technetium-99M sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine. Leuk- Lymphoma 1999;35:171–177.
25. Orlowsky RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 2004;45:187–188.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122